Monoclonal Antibody Treatment for COVID-19
Note: This page is intended for patients who have scheduled an appointment for mAb treatment. Please visit our mAB for Covid page to learn more about mAb and how to get treatment.
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of unapproved monoclonal antibody therapies (mAb) for the treatment of mild to moderate COVID-19 in patients who are considered high risk and are early in their symptom presentation and not receiving oxygen related to their diagnosis. People with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19. An order from a provider is required to receive mAb therapy. There is limited information known about the safety or effectiveness of using mAb therapy to treat people with COVID-19. If you have questions, please consult your physician.
Important things to know about your visit
- Masks are required in the building.
- No visitors are allowed for adult patients. Pediatric patients may be accompanied by one adult.
- The estimated treatment time for this visit is 3 hours, which includes treatment and monitoring.
How is the therapy administered?
This therapy is given through a vein (intravenous or IV) for at least one hour, followed by a one-hour observation period. Including registration and preparation, you should plan to spend approximately three hours at the infusion center. One dose is required for treatment.
Location information and instructions for parking and registration
We are currently offering mAb therapy at the following locations. There are specific parking, registration, and entrance instructions for patients receiving mAb therapy. Please arrive 15 minutes prior to your scheduled treatment time to register.
Click on the instructions below for your appointment location:
Locations for treatment
Currently we are offering the treatment at the locations below.
What are possible side effects?
- Allergic reactions, including anaphylaxis, can happen during and after infusion with mAb. Signs and symptoms of infusion related reactions may include: fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness. The medical staff will monitor patients during and immediately following treatment for signs of an adverse reaction.
- The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
- These are not all the possible side effects of mAb therapy as not a lot of people have been given this particular therapy. Serious and unexpected side effects may happen.
The CDC recommends deferring COVID-19 vaccination for at least 90 days after receiving monoclonal antibodies, as a precautionary measure until additional safety and efficacy information becomes available. If you have any questions, please consult your physician.
Read more about using monoclonal antibodies to treat COVID-19 from Journal of the American Medical Association.
Visit the National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment Guidelines website for more information on the emergency use of other medicines that are not approved by FDA to treat people with COVID-19.